Expression Profiling of Receptor-Activator of Nuclear Factor-Kappa B Ligand in Soft Tissue Tumors.

In conclusion, RANKL is expressed in subsets of soft tissue tumors with calcification, and denosumab is a potential therapeutic option for soft tissue tumors expressing RANKL.
PMID: 31189751 [PubMed - in process]

Source: The Tohoku Journal of Experimental Medicine - June 14, 2019 Category: Research Authors: Yamagishi T, Kawashima H, Ogose A, Ariizumi T, Oike N, Sasaki T, Hatano H, Ohashi R, Umezu H, Ajioka Y, Endo N Tags: Tohoku J Exp Med Source Type: research